1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,050 | 1,120 | 09:12 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Tevogen Bio Inc: Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives | 2 | GlobeNewswire (USA) | ||
| 03.06. | Tevogen Bio erweitert Bürofläche in New Jersey durch wichtigen Nachtrag | 3 | Investing.com Deutsch | ||
| 03.06. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Tevogen Bio erweitert KI-Initiative in der Immuntherapie-Entwicklung | 5 | Investing.com Deutsch | ||
| 30.05. | Tevogen Bio expands AI in immunotherapy development | 1 | Investing.com | ||
| 30.05. | Tevogen Bio Inc: Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships | 4 | GlobeNewswire (USA) | ||
| 26.05. | Tevogen Peports Plans to Increase the Target Population for TVGN 489 | 2 | Insider Monkey | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 23.05. | Tevogen expands target for COVID treatment to seniors | 1 | Investing.com | ||
| 23.05. | Tevogen erweitert Zielgruppe für COVID-Behandlung auf Senioren | 3 | Investing.com Deutsch | ||
| 23.05. | Tevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow | 119 | GlobeNewswire (Europe) | WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced a planned expansion of TVGN 489's target population to include patients... ► Artikel lesen | |
| 22.05. | Tevogen Bio Inc: Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting | 80 | GlobeNewswire (Europe) | WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of... ► Artikel lesen | |
| 14.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Tevogen Bio Inc: Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation | 107 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets... ► Artikel lesen | |
| 01.05. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 30.04. | Tevogen Bio Inc: CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment | 68 | GlobeNewswire (Europe) | WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that CD8 Technology Services LLC ("CD8") has signed a letter of intent... ► Artikel lesen | |
| 29.04. | Tevogen Bio shares surge on revenue forecast | 2 | Investing.com | ||
| 29.04. | Tevogen Bio-Aktien steigen nach Umsatzprognose | 3 | Investing.com Deutsch | ||
| 29.04. | Tevogen hebt Vorteile von DRS-Konten für Aktionäre hervor | 1 | Investing.com Deutsch | ||
| 29.04. | Tevogen highlights DRS account benefits for shareholders | 1 | Investing.com | ||
| 29.04. | Tevogen Bio Inc: Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts | 80 | GlobeNewswire (Europe) | WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today informed shareholders about several differences between holding shares in... ► Artikel lesen |
1 2 3 4 5 Weiter >>
88 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,685 | 0,00 % | Biotech Report: Qiagen und Biontech wenig bewegt, US-Sektor fest | (shareribs.com) Frankfurt / New York 06.06.2025 - Biotech-Werte zeigten sich im deutschen Handel durchwachsen. Biontech und Qiagen korrigierten leicht. An der Wall Street legte der Sektor hingegen deutlich... ► Artikel lesen | |
| AMGEN | 254,60 | -0,86 % | How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks? | ||
| NOVAVAX | 6,100 | -1,17 % | Novavax: CIC And Flu Vaccine Candidates Induce Immune Responses Similar To Licensed Comparators | WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported results of the initial cohort of COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,095 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 447,90 | -0,64 % | Regeneron Pharmaceuticals-Aktie heute stark gefragt: Kurs legt deutlich zu (450,0718 €) | Grund zur Freude haben Aktionäre von Regeneron Pharmaceuticals : Der Kurs der Aktie legt kräftig zu. Zu den Performancebesten an der Börse zählt zur Stunde die Aktie von Regeneron Pharmaceuticals. Im... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,810 | +0,56 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,120 | 0,00 % | COSCIENS Biopharma veröffentlicht zukunftsgerichtete Aussagen | ||
| BIOCRYST PHARMACEUTICALS | 8,834 | -1,63 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,410 | -0,10 % | BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,454 | +5,58 % | NurExone Biologic: Mit doppelter Geschwindigkeit zum Erfolg?! | ||
| ARROWHEAD PHARMACEUTICALS | 14,125 | +0,86 % | Arrowhead Pharmaceuticals auf Goldman Sachs-Konferenz: Strategische Markteinführungspläne | ||
| XOMA ROYALTY | 20,800 | -2,80 % | XOMA Royalty Corporation: XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements | Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,097 | +0,41 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,500 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio | - Robert Infarinato named VP, Strategic Development- Lisa Carson named as new VP, Finance and AdministrationMarlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp.... ► Artikel lesen |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.